Biosciences

#Biosciences #Neuroscience

Tuning in to the brain’s neural network

The brain: how much don’t we know? Dr Jim Ross, Chief Technology Officer and Co-founder of Axion BioSystems, asks and discusses the answers to this question. Epilepsy, amyotrophic lateral sclerosis (ALS), Alzheimer’s — we hear these brain disease names all the time, but it feels like we never hear about effective treatments or cures. While medical advances are gradually… Read More

#Editor's Choice #Exclusive Content #News

#Biosciences #CRO #Drug development #Immuno-oncology #Oncology

High demand for preclinical expertise fuels growth for Nottingham CRO 

Nottingham, UK-based contract research organisation (CRO) Cellomatics Biosciences has reported year-on-year organic revenue growth of 30% since its inception in 2015, as demand for its preclinical and early discovery phase laboratory services and expertise continues to increase.   Based at BioCity Nottingham, Cellomatics is a specialist preclinical CRO with expertise in five main therapeutic areas: oncology,… Read More

#News

#Assays #Biosciences #Protein chemistry / Proteomics

Protein-protein Interactions Using NanoBRET Technology

In this video, Dr Gary Allenby, CEO Aurelia Bioscience, describes a scientific poster on ‘Protein-protein Interactions Using NanoBRET Technology’. Historically, only solution-based assays were used to screen compounds in PPI, but a more physiological approach is to examine the interaction in living cells. However, there are very few… Read More

#News #Trending News #Videos

#Biosciences #Laboratory data #Microbiome

CN Bio licenses human gut microbiome modelling tool

CN Bio has licenced a novel tool for modelling the gut microbiome, GuMI, from Massachusetts Institute of Technology (MIT) and Northeastern University to investigate the direct interaction between the microbiome and gut and the wider effects of the microbiome on organs such as the liver and brain. Planned for commercial… Read More

#News

#Biomanufacturing #Biosciences #Biotherapeutics #Drug development #Therapeutics

Partnership to develop and manufacture biosimilars

Abzena and BioXpress Therapeutics have partnered to support biosimilar development for third party customers, creating an integrated solution between two service providers with expertise in biosimilar development and GMP manufacture. The partnership will ensure biosimilar drug developers benefit from an integrated approach to biosimilars spanning the range from design consultancy,… Read More

#News

#Biosciences #Drug development #Drug discovery #Narrated podcasts

The benefits of robust colony management in drug discovery

In this podcast John Couse, Vice President of Scientific Services at Taconic Biosciences discusses the benefits of a robust colony management solution/partner in the drug discovery success; how it can enable companies to scale through resource management and create efficiencies. Couse has extensive knowledge of colony managements solutions and outlines… Read More

#Podcasts

#Biosciences #Drug development #Drug discovery #Podcast

The benefits of robust colony management in drug discovery – podcast

In this podcast John Couse, Vice President of Scientific Services at Taconic Biosciences discusses the benefits of a robust colony management solution/partner in the drug discovery success; how it can enable companies to scale through resource management and create efficiencies. Couse has extensive knowledge of colony managements solutions and outlines… Read More

#News

#Biosciences #Clinical trials #Drug delivery #Drug discovery #High throughput screening #Therapeutics

Mini-library approach delivers an arsenal in drug development pipeline

Listen to this article on the DDW Podcast: Dr. Naganna Nimishetti, Chief of the Small Molecule Drug Discovery Division (SMDD) and Dr. Dun Yang, CEO/CSO of Anticancer Bioscience, a precision therapeutics company headquartered in Chengdu, China, explain how the company is identifying bioactive hits using libraries of less than 100 compounds. Read More

#Editor's Choice #Exclusive Content #News

#Biosciences #Healthcare #Pharma #Public health

Comment: investors ‘won’t appreciate the overhang’ following GSK spin-off

At an update to investors, GlaxoSmithKline (GSK) provided details of its strategy, outlook for growth and plans to create shareholder value, following the planned demerger in mid-2022 of its Consumer Healthcare business. An equity research expert suggests that while targets are friendly, investors will not get a completely clean… Read More

#News

#Biosciences #Biotherapeutics #Drug design #Drug development #Drug discovery

New approach will help identify drugs that can ‘glue’ proteins together

A new screening method that can test the effectiveness of therapeutic molecules designed to ‘glue’ proteins together in the body has been developed by researchers at the University of Birmingham and the University of Leicester. The research paves the way for drug developers to screen large numbers of potential new… Read More

#Editor's Choice #News

Scotland
#Bioeconomics #Biosciences #Biotechnology

Scottish fund supports biotechnology spin-outs

The Industrial Biotechnology Innovation Centre (IBioIC) has launched a Spin-Out Support Programme to provide funding for the commercialisation of industrial biotechnology concepts and the creation of spin-outs, helping drive the growth of Scotland’s bioeconomy. Funding will support researchers at Scottish universities to progress bio-based research and establish new companies, within… Read More

#News

#Biosciences #Drug delivery #Drug development #Drug discovery

Charnwood Group acquires Aurelia Bioscience

Aurelia Bioscience has announced that after ten years as a standalone biology contract research organisation, the company has been acquired by its collaborator Charnwood Molecular. Co-located in BioCity Nottingham, Aurelia Bioscience and Charnwood Molecular have previously jointly delivered research projects. This acquisition is said to allow both companies to formally… Read More

#News

#Biosciences #Life sciences #Mental health #Psychedelics

Early success on psychedelic healthcare investments

Neo Kuma Ventures has invested in seven innovative healthcare companies. The initial investments have proved successful with three of the seven companies going public this year, yielding between +180% and +680% return on initial investment. Following the launch of its fund in December 2020, Neo Kuma has invested more than… Read More

#News